Locally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy, followed by radical surgery, may be an effective treatment strategy for patients with PD-L1-positive LACC. This study aims to evaluate the efficacy and safety of preoperative treatment with iparomlimab and tuvonralimab-a bifunctional PD-1/CTLA-4 dual blocker-combined with chemotherapy for LACC.
1、Written informed consent
2、18-70 years old
3、Adequate organ function and ECOG of 0 ~1
4、Without systemic therapy at the time of enrollment
1、History of other malignancies within 3 years
2、Participate in other clinical trials at the same time
3、Active autoimmune disease, which needs systemic therapy
4、Uncontrolled infection, which needs systemic therapy
Fujian Cancer Hospital
Lead sponsor
Jiangsu Cancer Institute & Hospital
Collaborator
Fuzhou University Affiliated Provincial Hospital
Collaborator
First Affiliated Hospital of Fujian Medical University
Collaborator